Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit

Hims & Hers faces a shareholder class action following an FTC lawsuit alleging it shared sensitive consumer health data with advertising platforms including Meta and Snap, and used deceptive billing and cancellation practices. HIMS shares fell $4.32, or 14.73%, to $25.00 on July 29, 2026, after the FTC action was announced. The securities suit covers investors who bought HIMS between August 4, 2025 and July 29, 2026, with a November 2, 2026 lead-plaintiff deadline.

Analysis

The investable issue is not the shareholder suit; it is whether FTC-driven remediation impairs HIMS's low-friction acquisition and conversion funnel. If consent architecture, data-sharing controls, billing disclosures, or cancellation flows are redesigned, conversion rates can fall while customer-service and compliance costs rise. That creates a negative operating-leverage setup over the next 1-3 quarters: CAC may increase at the same time as revenue per acquired subscriber and retention are pressured.

HIMS is more exposed than scaled telehealth peers because its valuation has depended on rapid direct-to-consumer growth and efficient digital advertising rather than mature payer reimbursement economics. The key second-order risk is that advertisers and platforms reduce usable health-related targeting or require stricter event handling, weakening attribution and forcing broader, less efficient marketing spend. META and SNAP have negligible direct revenue exposure, but a broader FTC privacy precedent could modestly increase compliance friction for sensitive-category advertisers across their platforms.

The initial selloff should not be treated as a complete discount of risk absent evidence that remediation is narrow and user behavior is unchanged. Over 6-18 months, the larger downside is multiple compression if HIMS must demonstrate that growth is durable without aggressive conversion design; the upside case requires stable subscription retention, no material restriction on marketing measurement, and a settlement that avoids conduct remedies. Falsify the bearish thesis if management quantifies immaterial remediation costs, holds marketing efficiency and churn stable for two reporting periods, and provides guidance consistent with pre-action growth expectations.

Key Decisions for Investors

• Maintain a 1-3 month bearish bias on HIMS, preferably via put spreads rather than an unhedged short given high short-squeeze risk: buy 3-month 25/20 put spreads only if implied volatility is below the expected post-earnings move. Target a retest of the prior event low; exit if HIMS closes above the post-news recovery high or management reaffirms growth guidance with unchanged CAC and retention.
• For market-neutral exposure, pair short HIMS against long TDOC in equal beta-adjusted dollars over the next two earnings reports. The thesis is HIMS-specific funnel and compliance risk rather than a sector-wide telehealth demand deterioration; close the spread if TDOC also reports broad DTC regulatory or demand pressure.
• Do not short META or SNAP on this development alone. Instead, monitor disclosures on health-category ad restrictions, conversion-API policy changes, and sensitive-data enforcement; only consider a platform-risk hedge if such restrictions broaden beyond HIMS and affect measurable advertiser demand.
• Before increasing HIMS downside exposure, obtain the FTC complaint, management's remediation plan, revenue mix by subscription cohort, CAC/payback trend, refund/cancellation metrics, and any changes in paid-social attribution. These data determine whether the issue is a one-time legal charge or a structural hit to unit economics.